Department of Gastroenterology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago 8320000, Chile.
Department of Internal Medicine, Pontificia Universidad Católica de Chile, Santiago 8320000, Chile.
World J Gastroenterol. 2020 Dec 28;26(48):7693-7706. doi: 10.3748/wjg.v26.i48.7693.
Coronavirus disease 2019 (COVID-19) disease can frequently affect the liver. Data on hepatic histopathological findings in COVID-19 is scarce.
To characterize hepatic pathological findings in patients with COVID-19.
We conducted a systematic review with meta-analysis registered on PROSPERO (CRD42020192813), following PRISMA guidelines. Eligible trials were those including patients of any age and COVID-19 diagnosis based on a molecular test. Histopathological reports from deceased COVID-19 patients undergoing autopsy or liver biopsy were reviewed. Articles including less than ten patients were excluded. Proportions were pooled using random-effects models. statistic and were used to assess heterogeneity and levels of evidence, respectively.
We identified 18 studies from 7 countries; all were case reports and case series from autopsies. All the patients were over 15 years old, and 67.2% were male. We performed a meta-analysis of 5 studies, including 116 patients. Pooled prevalence estimates of liver histopathological findings were hepatic steatosis 55.1% [95% confidence interval (CI): 46.2-63.8], congestion of hepatic sinuses 34.7% (95%CI: 7.9-68.4), vascular thrombosis 29.4% (95%CI: 0.4-87.2), fibrosis 20.5% (95%CI: 0.6-57.9), Kupffer cell hyperplasia 13.5% (95%CI: 0.6-54.3), portal inflammation 13.2% (95%CI: 0.1-48.8), and lobular inflammation 11.6% (95%CI: 0.3-35.7). We also identified the presence of venous outflow obstruction, phlebosclerosis of the portal vein, herniated portal vein, periportal abnormal vessels, hemophagocytosis, and necrosis.
We found a high prevalence of hepatic steatosis and vascular thrombosis as major histological liver features. Other frequent findings included portal and lobular inflammation and Kupffer cell hyperplasia or proliferation. Further studies are needed to establish the mechanisms and implications of these findings.
2019 年冠状病毒病(COVID-19)疾病常可累及肝脏。有关 COVID-19 患者肝组织病理学发现的数据很少。
描述 COVID-19 患者的肝脏病理表现。
我们根据 PRISMA 指南进行了系统综述和荟萃分析(PROSPERO 注册:CRD42020192813)。合格的试验包括任何年龄的 COVID-19 患者,以及基于分子检测的 COVID-19 诊断。对接受尸检或肝活检的 COVID-19 死亡患者的组织病理学报告进行了回顾。排除了包含少于 10 名患者的文章。使用随机效应模型汇总比例。使用 统计量和 分别评估异质性和证据水平。
我们从 7 个国家的 18 项研究中确定了结果;所有研究均为尸检的病例报告和病例系列。所有患者年龄均大于 15 岁,其中 67.2%为男性。我们对包括 116 例患者的 5 项研究进行了荟萃分析。肝脏组织病理学发现的汇总患病率估计值为肝脂肪变性 55.1%(95%置信区间:46.2-63.8)、肝窦充血 34.7%(95%置信区间:7.9-68.4)、血管血栓形成 29.4%(95%置信区间:0.4-87.2)、纤维化 20.5%(95%置信区间:0.6-57.9)、库普弗细胞增生 13.5%(95%置信区间:0.6-54.3)、门脉炎症 13.2%(95%置信区间:0.1-48.8)和肝小叶炎症 11.6%(95%置信区间:0.3-35.7)。我们还发现了静脉流出梗阻、门静脉血栓形成、门静脉疝出、门周异常血管、噬血细胞现象和坏死的存在。
我们发现肝脂肪变性和血管血栓形成是主要的肝组织学特征,发生率较高。其他常见发现包括门脉和小叶炎症以及库普弗细胞增生或增殖。需要进一步的研究来确定这些发现的机制和意义。